Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine/Trastuzumab as First-Line Therapy for Advanced HER2-Overexpressing Pancreatic Carcinoma
DRKS00000600Phase 2Terminated
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, trastuzumab in pancreatic cancer (PC), sponsored by Universitätsklinikum Freiburg. Started Nov 2010; status: terminated.
02
Drugs
capecitabinetrastuzumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on DRKS00000600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000600.